407 related articles for article (PubMed ID: 33490314)
21. FGF23, PHEX, and MEPE regulation of phosphate homeostasis and skeletal mineralization.
Quarles LD
Am J Physiol Endocrinol Metab; 2003 Jul; 285(1):E1-9. PubMed ID: 12791601
[TBL] [Abstract][Full Text] [Related]
22. Ectopic expression of Klotho in fibroblast growth factor 23 (FGF23)-producing tumors that cause tumor-induced rickets/osteomalacia (TIO).
Kinoshita Y; Takashi Y; Ito N; Ikegawa S; Mano H; Ushiku T; Fukayama M; Nangaku M; Fukumoto S
Bone Rep; 2019 Jun; 10():100192. PubMed ID: 30627598
[TBL] [Abstract][Full Text] [Related]
23. What are the benefits of the anti-FGF23 antibody burosumab on the manifestations of X-linked hypophosphatemia in adults in comparison with conventional therapy? A review.
Lafage-Proust MH
Ther Adv Rare Dis; 2022; 3():26330040221074702. PubMed ID: 37180412
[TBL] [Abstract][Full Text] [Related]
24. Diagnosis and management of X-linked hypophosphatemia in children and adolescent in the Gulf Cooperation Council countries.
Al Juraibah F; Al Amiri E; Al Dubayee M; Al Jubeh J; Al Kandari H; Al Sagheir A; Al Shaikh A; Beshyah SA; Deeb A; Habeb A; Mustafa M; Zidan H; Mughal MZ
Arch Osteoporos; 2021 Mar; 16(1):52. PubMed ID: 33660084
[TBL] [Abstract][Full Text] [Related]
25. Identification of a novel FN1-FGFR1 genetic fusion as a frequent event in phosphaturic mesenchymal tumour.
Lee JC; Jeng YM; Su SY; Wu CT; Tsai KS; Lee CH; Lin CY; Carter JM; Huang JW; Chen SH; Shih SR; Mariño-Enríquez A; Chen CC; Folpe AL; Chang YL; Liang CW
J Pathol; 2015 Mar; 235(4):539-45. PubMed ID: 25319834
[TBL] [Abstract][Full Text] [Related]
26. New Therapies for Hypophosphatemia-Related to FGF23 Excess.
Athonvarangkul D; Insogna KL
Calcif Tissue Int; 2021 Jan; 108(1):143-157. PubMed ID: 32504139
[TBL] [Abstract][Full Text] [Related]
27. Intracranial phosphaturic mesenchymal tumors. A case report and review of literature.
Kojima D; Ohba S; Abe M; Suzuki A; Horibe S; Tateya I; Hasegawa M; Hirose Y
Neuropathology; 2022 Oct; 42(5):453-458. PubMed ID: 35880350
[TBL] [Abstract][Full Text] [Related]
28. Tumor-Induced Osteomalacia Localized and Excised After Pregnancy.
Sum M; Hoda ST; Rapp T; Zan E
AACE Clin Case Rep; 2021; 7(6):363-366. PubMed ID: 34765732
[TBL] [Abstract][Full Text] [Related]
29. Intact Fibroblast Growth Factor 23 Concentrations in Hypophosphatemic Disorders.
Ramos P; Larson B; Ashrafzadeh-Kian S; Ito N; Kato H; Bornhorst JA; Algeciras-Schimnich A
Endocr Pract; 2023 Mar; 29(3):193-198. PubMed ID: 36627024
[TBL] [Abstract][Full Text] [Related]
30. Clinical usefulness of measurement of fibroblast growth factor 23 (FGF23) in hypophosphatemic patients: proposal of diagnostic criteria using FGF23 measurement.
Endo I; Fukumoto S; Ozono K; Namba N; Tanaka H; Inoue D; Minagawa M; Sugimoto T; Yamauchi M; Michigami T; Matsumoto T
Bone; 2008 Jun; 42(6):1235-9. PubMed ID: 18396126
[TBL] [Abstract][Full Text] [Related]
31. Induction of FGF23-related hypophosphatemic osteomalacia by alcohol consumption.
Hidaka N; Kato H; Koga M; Katsura M; Oyama Y; Kinoshita Y; Fukumoto S; Makita N; Nangaku M; Ito N
Bone Rep; 2021 Dec; 15():101144. PubMed ID: 34901334
[TBL] [Abstract][Full Text] [Related]
32. A Rare Association Between Osteomalacia, Phosphaturic Mesenchymal Tumor, and Ovarian Cancer: A Case Report and Literature Review.
Mazza M; Arcidiacono GP; Hoxhaj I; Padoan V; Tasca G; Burei M; Sella S; Simioni P; Giannini S; Mocellin S
Calcif Tissue Int; 2024 May; ():. PubMed ID: 38806758
[TBL] [Abstract][Full Text] [Related]
33. [Tumor-induced osteomalacia caused by an FGF23-secreting myopericytoma : Case report and literature review].
Muro Bushart N; Tharun L; Oheim R; Paech A; Kiene J
Orthopade; 2020 Jan; 49(1):1-9. PubMed ID: 30937490
[TBL] [Abstract][Full Text] [Related]
34. Interim Analysis of a Phase 2 Open-Label Trial Assessing Burosumab Efficacy and Safety in Patients With Tumor-Induced Osteomalacia.
Imanishi Y; Ito N; Rhee Y; Takeuchi Y; Shin CS; Takahashi Y; Onuma H; Kojima M; Kanematsu M; Kanda H; Seino Y; Fukumoto S
J Bone Miner Res; 2021 Feb; 36(2):262-270. PubMed ID: 32967046
[TBL] [Abstract][Full Text] [Related]
35. Phosphaturic Mesenchymal Tumor Involving the Head and Neck: A Report of Five Cases with FGFR1 Fluorescence In Situ Hybridization Analysis.
Wasserman JK; Purgina B; Lai CK; Gravel D; Mahaffey A; Bell D; Chiosea SI
Head Neck Pathol; 2016 Sep; 10(3):279-85. PubMed ID: 26759148
[TBL] [Abstract][Full Text] [Related]
36. A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial Evaluating the Efficacy of Burosumab, an Anti-FGF23 Antibody, in Adults With X-Linked Hypophosphatemia: Week 24 Primary Analysis.
Insogna KL; Briot K; Imel EA; Kamenický P; Ruppe MD; Portale AA; Weber T; Pitukcheewanont P; Cheong HI; Jan de Beur S; Imanishi Y; Ito N; Lachmann RH; Tanaka H; Perwad F; Zhang L; Chen CY; Theodore-Oklota C; Mealiffe M; San Martin J; Carpenter TO;
J Bone Miner Res; 2018 Aug; 33(8):1383-1393. PubMed ID: 29947083
[TBL] [Abstract][Full Text] [Related]
37. Tumor induced osteomalacia - A long way toward correct diagnosis and management.
Filipová L; Zikán V; Krsek M; Netuka D; Michal M; Lazúrová I
Bone Rep; 2022 Jun; 16():101180. PubMed ID: 35281212
[TBL] [Abstract][Full Text] [Related]
38. Phosphaturic mesenchymal tumor with
Dwabe S; Chow W
Ther Adv Med Oncol; 2024; 16():17588359241232092. PubMed ID: 38455709
[TBL] [Abstract][Full Text] [Related]
39. Fibroblast growth factor receptor 1 (FGFR1) expression in phosphaturic mesenchymal tumors.
Tajima S; Fukayama M
Int J Clin Exp Pathol; 2015; 8(8):9422-7. PubMed ID: 26464698
[TBL] [Abstract][Full Text] [Related]
40. Tumour-induced osteomalacia: 18 months of 2-weekly burosumab treatment.
Aliberti L; Gagliardi I; Pontrelli M; Zatelli MC; Ambrosio MR
Endocrinol Diabetes Metab Case Rep; 2023 Jan; 2023(1):. PubMed ID: 37931408
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
